Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

Ann Oncol · 2014 · PMC3933250 · PMID 24567516

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

This had borderline significance in the sensitivity analysis per independent read; median duration of response was 3.9 and 5.0 months with PFE + CIL2W and PFE alone, respectively (HR versus PFE alone: 1.92 [95% CI 0.99–3.74]; P = 0.053).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.